Pfizer (PFE) Announces CFO Retirement

Pfizer (PFE) Announces Agreement to Supply 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to US Govt

November 18, 2021 6:45 AM EST

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), subject to regulatory authorization from the U.S. Food and Drug Administration (FDA). If approved or authorized, PAXLOVID, which originated in Pfizers... More

FDA plans to authorize Pfizer (PFE) - BioNTech (BNTX) boosters as soon as Thursday - NYT

November 16, 2021 5:20 PM EST

FDA plans to authorize Pfizer (NYSE: PFE) - BioNTech (NASDAQ: BNTX) boosters as soon as Thursday - NYT

... More

Pfizer files for U.S. authorization of promising COVID-19 antiviral pill

November 16, 2021 2:10 PM EST

By Michael Erman

(Reuters) - Pfizer Inc said on Tuesday it is seeking U.S. authorization of its experimental antiviral COVID-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial.

Pfizer said it completed submission of its application for emergency use authorization (EUA) of the drug, Paxlovid, with the U.S. Food and Drug Administration, including data from the drugmaker's clinical trial.

The oral drug could be a promising new weapon in the fight against the... More

Pfizer (PFE) Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate

November 16, 2021 2:00 PM EST

Pfizer Inc. today announced it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death. This submission to the U.S. Food and Drug Administration (FDA) includes clinical data from the Phase 2/3 EPIC-HR... More